Novavax Inc., a biotechnology company that develops vaccines for serious infectious diseases, saw its stock plummet 5.19% during intraday trading on Wednesday. This decline comes despite an initial premarket rally spurred by the recent CDC report on rising COVID-19 and flu cases across the United States.
The sell-off in Novavax's shares seems to be part of a broader market correction in the vaccine sector. Major vaccine makers like Moderna, Novo Nordisk, CureVac, and BioNTech, which initially rallied on the CDC's respiratory illness data, also experienced a pullback during intraday trading.
While the CDC's warning of increased COVID-19 and flu activity initially boosted investor confidence in vaccine manufacturers, it appears that the market has now priced in this news, leading to profit-taking and a subsequent decline in stock prices for companies like Novavax.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。